General Information of Drug Transporter (DT)
DT ID	DTD0142 Transporter Info
Gene Name	SLC22A16
Protein Name	Fly-like putative transporter 2
Gene ID	85413
UniProt ID	Q86VW1
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs12210538
Site of GPD	chr6:110438805 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0915/458 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Irrelevant to the likelihood of febrile neutropenia in patients (compare with Allele G)		[ 1]
Doxorubicin	N.A.	Febrile Neutropenia	Allele A is not associated with likelihood of febrile neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 1]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele A is not associated with likelihood of febrile neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 1]
Doxorubicin	N.A.	Breast Neoplasms	Allele A is not associated with likelihood of febrile neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 1]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased likelihood of drug toxicity in patients (compare with Allele A)		[ 2]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased likelihood of drug toxicity in patients (compare with Allele A)		[ 2]
Cyclophosphamide	N.A.	Drug Toxicity	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Drug Toxicity	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Cyclophosphamide	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Doxorubicin	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.		[ 2]
Genetic Polymorphism	rs6907567
Site of GPD	chr6:110456759 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.3141/1573 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele A)		[ 2]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele A)		[ 2]
Cyclophosphamide	N.A.	Drug Toxicity	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Drug Toxicity	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Cyclophosphamide	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Doxorubicin	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the decreased neutropenia risk in patients (compare with Genotype AA)		[ 4]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased neutropenia risk in patients (compare with Genotype AA)		[ 4]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the decreased neutropenia risk in patients (compare with Genotype AA)		[ 4]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Cyclophosphamide	N.A.	Neutropenia	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Doxorubicin	N.A.	Neutropenia	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Fluorouracil	N.A.	Neutropenia	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Doxorubicin	N.A.	Breast Neoplasms	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Fluorouracil	N.A.	Breast Neoplasms	Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 4]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Genetic Polymorphism	rs714368
Site of GPD	chr6:110456925 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.3139/1572 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele T)		[ 2]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele T)		[ 2]
Cyclophosphamide	N.A.	Neutropenia	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Doxorubicin	N.A.	Neutropenia	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Doxorubicinol	N.A.	Breast Neoplasms	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in patients (compare with genotypes tt + Ct)		[ 5]
Doxorubicin	N.A.	Drug Toxicity	Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.		[ 5]
Doxorubicin	N.A.	Breast Neoplasms	Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.		[ 5]
Doxorubicinol	N.A.	Breast Neoplasms	Genotype CC is associated with increased doxorubicin AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.		[ 5]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicinol	N.A.	Breast Neoplasm	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in patients (compare with genotypes tt + Ct)		[ 5]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with Genotype TT)		[ 4]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with Genotype TT)		[ 4]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with Genotype TT)		[ 4]
Cyclophosphamide	N.A.	Cardiotoxicity	Genotypes CC + CT is not associated with increased likelihood of cardiotoxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Doxorubicin	N.A.	Cardiotoxicity	Genotypes CC + CT is not associated with increased likelihood of cardiotoxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Cyclophosphamide	N.A.	Leukopenia	Genotypes CC + CT is associated with decreased likelihood of Leukopenia or Neutropenia when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Cyclophosphamide	N.A.	Neutropenia	Genotypes CC + CT is associated with decreased likelihood of Leukopenia or Neutropenia when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Doxorubicin	N.A.	Leukopenia	Genotypes CC + CT is associated with decreased likelihood of Leukopenia or Neutropenia when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Doxorubicin	N.A.	Neutropenia	Genotypes CC + CT is associated with decreased likelihood of Leukopenia or Neutropenia when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.		[ 7]
Cyclophosphamide	N.A.	Nausea	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Doxorubicin	N.A.	Nausea	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Fluorouracil	N.A.	Nausea	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Doxorubicin	N.A.	Breast Neoplasms	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Fluorouracil	N.A.	Breast Neoplasms	Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.		[ 4]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.		[ 5]
Doxorubicinol	N.A.	Breast Neoplasms	Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.		[ 5]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Doxorubicin	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.		[ 5]
Doxorubicinol	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.		[ 5]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.		[ 2]
Genetic Polymorphism	rs723685
Site of GPD	chr6:110442672 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0881/441 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele A)		[ 2]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of dose delay in patients (compare with Allele A)		[ 2]
Cyclophosphamide	N.A.	Drug Toxicity	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Doxorubicin	N.A.	Drug Toxicity	Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 2]
Cyclophosphamide	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Doxorubicin	N.A.	Febrile Neutropenia	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 3]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Cardiotoxicity	Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Cardiotoxicity	Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclophosphamide	N.A.	Cardiotoxicity	Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.		[ 2]
References
1	Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. PLoS One. 2016 Dec 30;11(12):e0168519.
2	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
3	Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array. Eur J Clin Pharmacol. 2018 Oct;74(10):1291-1298.
4	Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
5	Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007 Jun;8(6):567-75.
6	Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients. Xenobiotica. 2024 Mar;54(3):160-170.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.